Diabetic polyneuropathy (DPN) is a common neurological complication of diabetes mellitus. The most common DPN type is distal symmetric, predominantly sensory, polyneuropathy (DSPN), often accompanied by pain syndrome. This article is aimed to evaluate of ipidacrine (Ipigrix) efficacy in complex DSPN therapy. The dynamics of clinical and neurophysiological manifestations of DPN in the form of the appearance of previously absent tendon reflexes, a decrease in the area and severity of sensory disturbances, the intensity of neuropathic pain, an increase in the amplitude of motor and sensory responses in response to stimulation of peripheral nerves indicates the activation of reinnervation processes against the background of therapy using ipidacrine. Assessing the positive effect on the restoration of the structure and function of peripheral nerves, good tolerability and safety of ipidacrine (Ipigrix), it is possible to recommend the drug in patients with DSPN.

Nervous system tumors are not the most common cancer in the population. However, the clinical manifestations of brain tumors (BTs) are very multifaceted and can mask a wide range of pathologies, which poses a difficult task for doctors to suspect a cancer and start treating the patient as soon as possible. An atypical clinical course of the BTs is described, which caused a rather long path to diagnosis in a middle-aged patient.

Diabetic polyneuropathy (DPN) is the most common neurological complication of diabetes mellitus. The most common type of DPN is distal symmetric, predominantly sensory, polyneuropathy. Chronic hyperglycemia plays a key role in DPN pathogenesis. It leads to accumulation of advanced glycation end products in tissues, including vasa nevrorum that supply peripheral nerves with oxygen. Thorough diagnostic approach to DPN is crucial for early detection of this condition. Early diagnosis and treatment slow DPN progression rates and leads to symptom reduction. Long-lasting metformin therapy may cause vitamin B deficiency. This article describes a comprehensive approach to the treatment of patient with type 2 diabetes and symptomatic diabetic and vitamin deficiency neuropathy. Apart from DM therapy, the patient received pathogenesis-based therapy of DPN with alpha-lipoic acid and a combination of vitamins B1, B6 and B12. Such pathogenesis-based approach has shown to decrease severity of DPN symptoms and reduce sensory ataxia.